Cargando…

Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver

Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with clostridial collagenase ointment (CCO) or silver-containing products, both in combination with sharp debridement as needed. Approach: One hundred two subjects with qualifying DFUs were randomized to daily treatment with eithe...

Descripción completa

Detalles Bibliográficos
Autores principales: Motley, Travis A., Caporusso, Joseph M., Lange, Darrell L., Eichelkraut, Robert A., Cargill, David Innes, Dickerson, Jaime E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203225/
https://www.ncbi.nlm.nih.gov/pubmed/30374419
http://dx.doi.org/10.1089/wound.2018.0784
_version_ 1783365838997291008
author Motley, Travis A.
Caporusso, Joseph M.
Lange, Darrell L.
Eichelkraut, Robert A.
Cargill, David Innes
Dickerson, Jaime E.
author_facet Motley, Travis A.
Caporusso, Joseph M.
Lange, Darrell L.
Eichelkraut, Robert A.
Cargill, David Innes
Dickerson, Jaime E.
author_sort Motley, Travis A.
collection PubMed
description Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with clostridial collagenase ointment (CCO) or silver-containing products, both in combination with sharp debridement as needed. Approach: One hundred two subjects with qualifying DFUs were randomized to daily treatment with either CCO or a silver-containing product for 6 weeks followed by a 4 -week follow-up period. The primary outcome was the mean percent reduction in DFU area. A secondary outcome was the incidence of ulcer infections between groups. Results: At the end of treatment, the mean percent reduction in area from baseline of DFUs treated with CCO was 62% (p < 0.0001) and with silver was 40% (p < 0.0001). The difference between groups—22%—was not statistically significant (p = 0.071). Among ulcers closed by the end of treatment, the mean time to closure was 31.1 ± 9.0 days versus 37.1 ± 7.7 days, respectively (not statistically significant). There was a numerically greater incidence of target ulcer infections in the silver group (11, 21.6%) than in the CCO group (5, 9.8%; p = 0.208). No clinically relevant safety signals were identified in either group. Innovation: CCO treatment can progress a wound toward closure. Ulcer infection prophylaxis may not be sacrificed when treating DFU with CCO in lieu of silver-containing products. Conclusion: Both CCO and silver-containing products promote significant reduction in DFU area over 6 weeks of treatment with no clinically relevant safety concerns. Mean percent reduction in lesion area was numerically (22%) but not significantly greater with CCO compared to silver, as was time to ulcer closure, with an incidence of ulcer infection at least as low as for silver-containing products.
format Online
Article
Text
id pubmed-6203225
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-62032252018-10-29 Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver Motley, Travis A. Caporusso, Joseph M. Lange, Darrell L. Eichelkraut, Robert A. Cargill, David Innes Dickerson, Jaime E. Adv Wound Care (New Rochelle) Discovery Express Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with clostridial collagenase ointment (CCO) or silver-containing products, both in combination with sharp debridement as needed. Approach: One hundred two subjects with qualifying DFUs were randomized to daily treatment with either CCO or a silver-containing product for 6 weeks followed by a 4 -week follow-up period. The primary outcome was the mean percent reduction in DFU area. A secondary outcome was the incidence of ulcer infections between groups. Results: At the end of treatment, the mean percent reduction in area from baseline of DFUs treated with CCO was 62% (p < 0.0001) and with silver was 40% (p < 0.0001). The difference between groups—22%—was not statistically significant (p = 0.071). Among ulcers closed by the end of treatment, the mean time to closure was 31.1 ± 9.0 days versus 37.1 ± 7.7 days, respectively (not statistically significant). There was a numerically greater incidence of target ulcer infections in the silver group (11, 21.6%) than in the CCO group (5, 9.8%; p = 0.208). No clinically relevant safety signals were identified in either group. Innovation: CCO treatment can progress a wound toward closure. Ulcer infection prophylaxis may not be sacrificed when treating DFU with CCO in lieu of silver-containing products. Conclusion: Both CCO and silver-containing products promote significant reduction in DFU area over 6 weeks of treatment with no clinically relevant safety concerns. Mean percent reduction in lesion area was numerically (22%) but not significantly greater with CCO compared to silver, as was time to ulcer closure, with an incidence of ulcer infection at least as low as for silver-containing products. Mary Ann Liebert, Inc., publishers 2018-10-01 2018-10-11 /pmc/articles/PMC6203225/ /pubmed/30374419 http://dx.doi.org/10.1089/wound.2018.0784 Text en © Travis A. Motley, et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Discovery Express
Motley, Travis A.
Caporusso, Joseph M.
Lange, Darrell L.
Eichelkraut, Robert A.
Cargill, David Innes
Dickerson, Jaime E.
Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
title Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
title_full Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
title_fullStr Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
title_full_unstemmed Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
title_short Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
title_sort clinical outcomes for diabetic foot ulcers treated with clostridial collagenase ointment or with a product containing silver
topic Discovery Express
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203225/
https://www.ncbi.nlm.nih.gov/pubmed/30374419
http://dx.doi.org/10.1089/wound.2018.0784
work_keys_str_mv AT motleytravisa clinicaloutcomesfordiabeticfootulcerstreatedwithclostridialcollagenaseointmentorwithaproductcontainingsilver
AT caporussojosephm clinicaloutcomesfordiabeticfootulcerstreatedwithclostridialcollagenaseointmentorwithaproductcontainingsilver
AT langedarrelll clinicaloutcomesfordiabeticfootulcerstreatedwithclostridialcollagenaseointmentorwithaproductcontainingsilver
AT eichelkrautroberta clinicaloutcomesfordiabeticfootulcerstreatedwithclostridialcollagenaseointmentorwithaproductcontainingsilver
AT cargilldavidinnes clinicaloutcomesfordiabeticfootulcerstreatedwithclostridialcollagenaseointmentorwithaproductcontainingsilver
AT dickersonjaimee clinicaloutcomesfordiabeticfootulcerstreatedwithclostridialcollagenaseointmentorwithaproductcontainingsilver